Galan A, et al. - Whether or not sarcopenia and/or abdominal fat composition could predict postoperative outcomes for patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) for pseudomyxoma peritonei (PMP) and peritoneal mesothelioma (PM) was investigated. Researchers retrospectively studied all patients who underwent a complete CRS-HIPEC for PMP and PM, between January 2009 and September 2017. Findings suggest that in these patients, computed tomography (CT) measured sarcopenia was an independent predictive factor for overall survival, however, it seemed not valuable for forecasting postoperative morbidity.